Mumbai, Sep 11 (UNI) Pharma Major, Zydus Cadila has received the tentative approval from the USFDA for Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg (US RLD - Januvia Tablets).

It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad,company said in a filing with BSE.

Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4)

inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high.

The group now has 217 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

UNI JS NV RSU 1427